NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

A timeline of “2025-2026” was therefore set for the launch. Vivo Nex 3, a 2019 production-grade phone with no bezels on two sides. Vivo Unlike certain Chinese brands that have attempted to ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Nexiguran ziclumeran (nex-z, also known as NTLA-2001) is an investigational in vivo CRISPR-based therapy designed to inactivate the transthyretin (“TTR”) gene in liver cells, thereby ...

The Vivo Y300 5G features a 6.67-inch (2400 ×1080 pixels) Full HD+ E4 AMOLED screen with a 120Hz refresh rate. It is powered by the Snapdragon 4 Gen 2 processor paired with 8GB RAM and up to ...

Vivo X200 Pro is the latest entrant in the flagship segment of phones in India. However, unlike the other flagship phones we have seen, the essence of the latest X200 Pro is straight away its ...

vivo launched the Y28 in January with the Dimensity 6020 SoC, and today, the brand unveiled its successor, powered by the Dimensity 6300 chip. The vivo Y29 runs Android 14-based Funtouch OS 14 out ...

vivo is currently working on the X200 Ultra, its absolute flagship smartphone for 2025. Today a new leak from China brings us a few interesting details about its cameras. The phone will reportedly ...

Vivo is gearing up to release its flagship smartphone for 2025, the Vivo X200 Ultra, and a recent leak has revealed some exciting details about its camera setup. Known for pushing boundaries in ...